



(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/4439 (2006.01)  
A61K 9/20 (2006.01) A61K 9/28 (2006.01)  
A61K 31/4184 (2006.01)

(21) International Application Number:

PCT/EP2013/071803

(22) International Filing Date:

17 October 2013 (17.10.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2012/12083 19 October 2012 (19.10.2012) TR  
2013/11483 1 October 2013 (01.10.2013) TR

(71) Applicant: **SANOVEL ILAC SANAYI VE TICARET A.S.** [TR/TR]; Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye, Sariyer, 34460 Istanbul (TR).

(72) Inventors: **TÜRKYILMAZ, Ali**; Sanovel Ilac Sanayi Ve Ticaret A.S., Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye, 34460 Istanbul (TR). **TURP, Ali Hasan**; Sanovel Ilac Sanayi Ve Ticaret A.S., Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye, 34460 Istanbul (TR). **SAYDAM, Mehmetap**; Sanovel Ilac Sanayi Ve Ticaret A.S., Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye, 34460 Istanbul (TR).

(74) Agent: **SEVINC, Erkan**; Istanbul Patent & Trademark Consultancy Ltd., Plaza-33, Buyukdere cad. 33/16 Sisli, 34381 Istanbul (TR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2014/060561 A1

(54) Title: ORAL PHARMACEUTICAL FORMULATIONS COMPRISING DABIGATRAN

(57) Abstract: The present invention relates to a novel pharmaceutical enteric coated pellet formulations comprising dabigatran etexilate free base as an active agent and at least one pharmaceutically acceptable excipient. The present invention further relates to a highly soluble and stable formulations comprising dabigatran etexilate free base as an active agent.

## Description


### Oral Pharmaceutical Formulations Comprising Dabigatran

#### 5 Technical Field

The present invention relates to a novel pharmaceutical enteric coated pellet formulations comprising dabigatran etexilate free base as an active agent and at least one pharmaceutically acceptable excipient. The present invention further relates to a highly soluble and stable formulations comprising dabigatran etexilate free base as an active agent.  
10 active agent.

#### Background of the Invention

Dabigatran etexilate (Formula 1), which is already known from WO 98/37075, is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.  
15 in patients with non-valvular atrial fibrillation.



Formula 1: Dabigatran etexilate

The methane sulphonic acid addition salt of dabigatran etexilate, which is commercially available under the trade name PRADAXA®, is disclosed in  
20 EP1870100, wherein also disclosed, pellet formulation of dabigatran etexilate

methanesulphonate. This formulation is formulated with a core material consisting of organic acid and an active layer which encloses the core.

5 Apart from the methanesulfonate salt of dabigatran etexilate, other acid addition salts of the compound are provided in prior art. For example, WO2012/077136 is directed to the oxalate salt of dabigatran etexilate and besides, its hydrochloride salt is identified in EP1877395. These various form of dabigatran etexilate are prepared to facilitate the development of pharmaceutical formulation. An active agent should meet some physicochemical requirements in order to be capable of being used in  
10 pharmaceutical formulations. These requirements considerably depend on the physicochemical properties of the active agent used in pharmaceutical formulation.

These various dabigatran etexilate salts disclosed in prior art, were compared for their physicochemical properties like water solubility, stability, and shelf-life which are  
15 important for the development of pharmaceutical formulations. Also, it is known in the prior art that dabigatran etexilate is a weakly basic compound and therefore it has high solubility in acidic media.

Absorption of the active substances generally occurs in the small intestine due to a  
20 large surface area and the slow peristaltic movements of the small intestine that has a basic media. However, absorption from the stomach that has an acidic media is negligibly low due to the fast peristaltic movements and the high the surface area of the stomach. Thus the dissolution of the active substances in the small intestine, a basic media, is important. Dabigatran, is weakly basic, should be dissolved in basic  
25 environments and the dissolution of dabigatran should be pH independent.

However, there is still a need for oral pharmaceutically formulations comprising dabigatran etexilate that has pH independent release.

### 30 **Object of the Invention**

The main object of the present invention is to use of dabigatran etexilate free base in the preparation of a medicament to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Another object of the present invention is to obtain a stable and highly soluble pharmaceutical formulations comprising dabigatran etexilate free base as an active agent and at least one pharmaceutically acceptable excipient.

- 5 Another object of the present invention is to provide a pharmaceutical formulation comprising dabigatran etexilate free base that has pH-independent release without a dose-dumping.

10 the purity degree of dabigatran etexilate free base render more stable the pharmaceutical formulation during production and storage.

Another object of the present invention is to provide stable pharmaceutical products during shelf-life, wherein the products comprising dabigatran etexilate free base with a reduced moisture content.

15

#### **Detailed Description of the Invention**

The present invention is related to novel enteric coated pellet formulations comprising dabigatran etexilate free base as active agent.

- 20 As used herein, the term "dabigatran etexilate free base" refers to dabigatran etexilate which is free from other forms of the active moiety, especially acid addition salts.

The dabigatran etexilate free base of the present invention is formed as a solid form which is easily handled and particularly well suited to the pharmaceutical formulation.

- 25 It has been surprisingly discovered that the dabigatran etexilate free base has physicochemical properties (e.g. purity, non-hygroscopicity, solubility) which are more suitable to develop a pharmaceutical formulation, than other forms of dabigatran etexilate, e.g. salts. According to present invention, it has also been discovered that the pharmaceutical formulation has improved physicochemical properties such as  
30 stability, dissolution, storage and flowability, compared to pharmaceutical formulations described in prior art.

- 35 According to another embodiment of the present invention, said oral solid pharmaceutical formulation is formulated as enteric coated pellet. Pellets provide a reduction in the dosage regimen and gastrointestinal irritation moreover controlling the drug release and increasing the absorption of the active ingredient. Also one of the

advantageous properties of the pellet formulations is being good candidates for the delivery of the drug substances because the pellet formulations minimize the dose dumping effect. The reproducibility of the pellet formulations is also much better than the reproducibility of the single-unit dosage forms. They are suitable systems for film coating with respect to the low surface area-volume ratios. Also, resistance to external factors such as moisture, air and light are the most advantageous properties of these dosage forms. Due to the mentioned reasons, the preferred dosage form is enteric coated pellet.

10 According to an embodiment of the present invention, using methacrylic acid - ethyl acrylate copolymer (1:1) as an enteric coating agent enhances an increase in the solubility of the active agent in the said formulation. Methacrylic acid - ethyl acrylate copolymer (1:1), an enteric polymer, interacts with the cationic groups of dabigatran etexilate and increases the solubility of dabigatran etexilate. Methacrylic acid - ethyl acrylate copolymer (1:1) is an important factor which controls the solubility of formulations of weakly basic active agents when compared to nonionic coating such as hydroxypropyl methylcellulose (HPMC). In addition, methacrylic acid - ethyl acrylate copolymer (1:1) providing effective and stable coatings is a suitable coating agent for weakly basic active agents such as dabigatran etexilate. In the prior art studies, it is found that using polyionic polymers such as methacrylic acid - ethyl acrylate copolymer (1:1) resulted in reduced water uptake and matrix permeability. Thus, stable formulations over the shelf life are obtained by minimizing the penetration of moisture and air into the pellets. Also, methacrylic acid - ethyl acrylate copolymer (1:1) increases the absorption of dabigatran etexilate by providing dissolution of dabigatran etexilate in the upper parts of the small intestine rather than the stomach. The amount of methacrylic acid- ethacrylate copolymer (1:1) is in the range of 0.1 to 50.0%, preferably in the range of 0.5 to 40.0% by total weight of the formulation.

30 According to another embodiment of the present invention, it has been observed that adding appropriate buffering agents to the matrix core and coating the dosage form with appropriate coating agents are enough for increasing the solubility of dabigatran etexilate which is a weakly basic compound and for a pH-independent dissolution of dabigatran etexilate. It has been surprisingly discovered that the use of fumaric acid as a buffer agent is effective in increasing the solubility of the active ingredient. The solubility of fumaric acid is lower than that of the other buffering agents. Accordingly, fumaric acid keeps the pH of the micro-environment low, for a long time whilst remain

undissolved in tablets or capsules and increases the solubility of the active agent. Also, fumaric acid aids the spheronisation of the pellets due to lubricant property of fumaric acid and contributes the production of fine pellets. By means of fumaric acid, the surface area of the obtained fine pellets is increased and as a result the solubility of the formulation is increased. The amount of fumaric acid is in the range of 0.1 to 50.0%, preferably in the range of 0.5 to 40.0% by total weight of the formulation.

According to another embodiment of the present invention, in said formulation setting the weight ratio of fumaric acid to methacrylic acid - ethyl acrylate copolymer (1:1) between 80:1 and 1:80 exhibited a synergistic effect on enhancing the stability and solubility of the tablet.

As used herein, the term "methacrylic acid - ethyl acrylate copolymer (1:1)" refers to an anionic copolymer comprising methacrylic acid and ethyl acrylate. The ratio of the carboxylic groups to ester groups in this anionic polymer is about 1:1. The polymer dry weight content of this polymer is between 90.0% to 99.0%, preferably 93.0% to 97.0, more preferably 95.0% based on the total weight of the polymer.

According to an embodiment of the present invention, in said formulation using polyvinylpyrrolidone as a binder increases the stability of the formulation by increasing the viscosity. Polyvinylpyrrolidone increases the solubility of the formulation due to its disintegrant property of polyvinylpyrrolidone. Polyvinylpyrrolidone, is a good binder, aids to the pelletizing process by holding together active agents and excipients. Compared to using non-soluble binders such as gum arabic in the prior art, using PVP is advantageous for the formulations comprising active agents having solubility problems due to high solubility of PVP in water and other polar solvents. Polyvinylpyrrolidone in an amount of 0.05 to 35.00%, preferably 0.1 to 25.00% by weight of total formulation contributes to increasing the stability, the solubility and the shelf life of the formulation.

According to another embodiment of the present invention, besides dabigatran etexilate, methacrylic acid - ethyl acrylate copolymer (1:1), fumaric acid, and polyvinylpyrrolidone, the said formulation further comprises at least one pharmaceutically acceptable excipient selected from the group consisting of diluents, controlled release agents, lubricants, and glidants.

Suitable diluents may include but not limited to sugars, microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dibasic calcium phosphate, sodium chloride, dextrans, lactitol, maltodextrin, sucrose-  
5 maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate and mixtures thereof.

The enteric coated pellets according to the present invention in addition to methacrylic acid- ethacrylate copolymer (1:1) may be coated with polyvinyl acetate,  
10 cellulose acetate phthalate, ammonium methacrylate copolymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose acetate succinate, hydrogels, carboxyvinyl polymer, sodium alginate, sodium carmellose, calcium carmellose, polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol mixtures, gelatine, starch, polyvinylpyrrolidone,  
15 microcrystalline cellulose, collagen, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, carboxymethyl cellulose, carnauba wax, pectin, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, bentonit, laponit, setostearyl alcohol, polyoxyethylen-alkyl ethers, hyaluronic acid, guar gum, cocoa oil, paraffin, hydrogenated vegetable oil, cetyl alcohol, stearyl alcohol, stearic  
20 acid, xanthane gum or mixtures thereof.

Suitable lubricants may include but not limited to magnesium stearate, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate,  
25 polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate and mixtures thereof.

Suitable glidants may include but not limited to colloidal silicon dioxide, silicon dioxide, talc, aluminium silicate, silica and mixtures thereof.

30

According to an embodiment of the present invention, pharmaceutical formulations of the present invention may be prepared by conventional technology well known to those skilled in the art such as extrusion / spheronisation, spray drying and the like. The obtained pellets have at least one coating due to using methacrylic acid-  
35 ethacrylate copolymer (1:1).

**Examples:****Example 1:**

<i>Content</i>	<i>Amount (%)</i>
Dabigatran etexilate	15.0 - 60.0
Dibasic calcium phosphate	5.0 - 40.0
Fumaric acid	0.5 - 40.0
Polyvinylpyrrolidone (PVP)	0.1 - 25.0
Methacrylic acid- ethacrylate copolymer (1:1)	0.5 - 40.0
Silicon dioxide	0.1 - 0.2
Magnesium stearate	0.25 - 2.0

## 5 Production method:

Dabigatran etexilate, dibasic calcium phosphate, and fumaric acid are mixed and this mixture granulated with hydroalcoholic/ alcoholic PVP solution. The granules that are passed through extruder are exposed to spheronization process to obtain pellets. The obtained pellets are coated with methacrylic acid- ethacrylate copolymer (1:1) solution. The coated pellets are mixed with silicon dioxide and then they are mixed with magnesium stearate for a short time. The obtained pellets are filled to capsules.

10

**Example 2:**

<i>Content</i>	<i>Amount (%)</i>
Dabigatran etexilate	15.0 - 60.0
Fumaric acid	0.5 - 40.0
Polyvinylpyrrolidone (PVP)	0.1 - 25.0
Methacrylic acid- ethacrylate copolymer (1:1)	0.5 - 40.0
Silicon dioxide	0.1 - 0.2
Magnesium stearate	0.25 - 2.0

## 15 Production method:

The hydroalcoholic/ alcoholic solution that is obtained as a result of mixing with dabigatran etexilate, fumaric acid, and PVP, is pelletized in the spray drier. The obtained pellets are coated with methacrylic acid- ethacrylate copolymer (1:1)



solution. The coated pellets are mixed with silicon dioxide and then they are mixed with magnesium stearate for a short time. The obtained pellets are filled to capsules.

**Example 3:**

<i>Content</i>	<i>Amount (%)</i>
Dabigatran etexilate	15.0 - 60.0
Fumaric acid	0.5 - 40.0
Polyvinylpyrrolidone (PVP)	0.1 - 25.0
Sugar pellets	5.0 - 90.0
Methacrylic acid- ethacrylate copolymer (1:1)	0.5 - 40.0
Polyvinyl acetate	5.0 - 40.0
Silicon dioxide	0.1 - 0.2
Magnesium stearate	0.25 - 2.0

5

Production method:

The hydroalcoholic/ alcoholic solution/ dispersion is prepared by mixing with dabigatran etexilate, fumaric acid, and PVP. The sugar pellets are coated with this solution/ dispersion. Then the obtained pellets are coated with methacrylic acid-ethacrylate copolymer (1:1) solution, then the coated pellets are coated with polyvinyl acetate solution. The coated pellets are mixed with silicon dioxide and then they are mixed with magnesium stearate for a short time. The obtained pellets are filled to capsules.

15

**CLAIMS**

1. An enteric coated tablet formulation, comprising dabigatran etexilate free base as an active agent.  
5
2. The pharmaceutical formulation according to claim 1, further comprising methacrylic acid- ethacrylate copolymer (1:1) as an enteric coating agent.
3. The pharmaceutical formulation according to claim 2, wherein the amount of  
10 methacrylic acid- ethacrylate copolymer (1:1) is in the range of 0.1 to 50.0% by total weight of the formulation.
4. The pharmaceutical formulation according to claim 3, wherein the amount of  
15 methacrylic acid- ethacrylate copolymer (1:1) is in the range of 0.5 to 40.0% by total weight of the formulation.
5. The pharmaceutical formulation according to any of the preceding claims, further comprising fumaric acid as a buffering agent.
- 20 6. The pharmaceutical formulation according to claim 5, wherein the amount of fumaric acid is in the range of 0.1 to 50.0% by total weight of the formulation.
7. The pharmaceutical formulation according to claim 6, wherein the amount of fumaric acid is in the range of 0.5 to 40.0% by total weight of the formulation.  
25
8. The pharmaceutical formulation according to claims 2- 7, wherein the weight ratio of fumaric acid to methacrylic acid- ethacrylate copolymer (1:1) is between 80:1 and 1:80 in the formulation.
- 30 9. The pharmaceutical formulation according to any of the preceding claims, further comprises polyvinylpyrrolidone as a binder.
10. The pharmaceutical formulation according to claim 9, wherein the amount of polyvinylpyrrolidone is in the range of 0.05 to 35.0% by total weight of the  
35 formulation.

11. The pharmaceutical formulation according to claim 10, wherein the amount of polyvinylpyrrolidone is in the range of 0.1 to 25.0% by total weight of the formulation.

**INTERNATIONAL SEARCH REPORT**

International application No  
PCT/EP2013/071803

A. CLASSIFICATION OF SUBJECT MATTER  
 INV. A61K9/00 A61K9/20 A61K31/4184 A61K31/4439 A61K9/28  
 ADD.  
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
 Minimum documentation searched (classification system followed by classification symbols)  
 A61K  
 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2005/038077 A1 (KOHLRAUSCH ANJA [DE]) 17 February 2005 (2005-02-17) claim 1 -----	1-11
Y	WO 2008/009638 A2 (BOEHRINGER INGELHEIM INT [DE]; BOEHRINGER INGELHEIM PHARMA [DE]; CLEME) 24 January 2008 (2008-01-24) claims 1,12-14 -----	1-11
X	WO 2010/055021 A1 (BOEHRINGER INGELHEIM INT [DE]; REILLY PAUL A [US]) 20 May 2010 (2010-05-20) page 16, line 10 - line 15; claims 1-84 page 19, line 20 - line 23 page 14, paragraph 2 ----- -/--	1-11

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  2 April 2014	Date of mailing of the international search report  10/04/2014
---	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Kardas-Llorens, Eyüp
--	--

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2013/071803

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2006/103206 A2 (BOEHRINGER INGELHEIM INT [DE]; BOEHRINGER INGELHEIM PHARMA [DE]; REILL) 5 October 2006 (2006-10-05) page 1 - page 2 page 8, paragraph 2; claim 1 page 36, line 13 - line 29; examples 3,4 -----	1-11
X	US 6 087 380 A (HAUEL NORBERT [DE] ET AL) 11 July 2000 (2000-07-11) column 19 - column 20; example 113 -----	1-11
Y	NISHIO HITOSHI ET AL: "New therapeutic option for thromboembolism--dabigatran etexilate", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY PUBLICATIONS LTD, LONDON, UK, vol. 9, no. 14, 1 October 2008 (2008-10-01), pages 2509-2517, XP009127716, ISSN: 1465-6566, DOI: 10.1517/14656566.9.14.2509 page 2511 - page 2515 -----	1-11
Y	BAETZ B E ET AL: "Dabigatran etexilate: An oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases", PHARMACOTHERAPY : THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, BOSTON, US, vol. 28, no. 11 PART 1, 1 November 2008 (2008-11-01), pages 1354-1373, XP008100341, ISSN: 0277-0008 the whole document -----	1-11

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2013/071803

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 2005038077	A1	17-02-2005	AR 045732 A1	09-11-2005
			AT 394094 T	15-05-2008
			CA 2535810 A1	03-03-2005
			DE 10337697 A1	24-03-2005
			DK 1658056 T3	08-09-2008
			EP 1658056 A1	24-05-2006
			ES 2307041 T3	16-11-2008
			JP 4977462 B2	18-07-2012
			JP 2007502788 A	15-02-2007
			PE 03422005 A1	17-06-2005
			PT 1658056 E	23-06-2008
			SI 1658056 T1	31-08-2008
			US 2005038077 A1	17-02-2005
			UY 28468 A1	31-03-2005
WO 2005018615 A1	03-03-2005			
-----				
WO 2008009638	A2	24-01-2008	AU 2007276205 A1	24-01-2008
			BR PI0715492 A2	19-03-2013
			CA 2657266 A1	24-01-2008
			EA 200900091 A1	30-06-2009
			EC SP099049 A	27-02-2009
			EP 2043631 A2	08-04-2009
			JP 2009543842 A	10-12-2009
			KR 20090029849 A	23-03-2009
			TW 200817001 A	16-04-2008
			US 2008039391 A1	14-02-2008
			WO 2008009638 A2	24-01-2008
			-----	
WO 2010055021	A1	20-05-2010	AR 074313 A1	05-01-2011
			AU 2009315729 A1	20-05-2010
			CA 2738883 A1	20-05-2010
			CN 102209544 A	05-10-2011
			CN 103356614 A	23-10-2013
			CO 6361938 A2	20-01-2012
			EA 201100756 A1	30-12-2011
			EC SP11011030 A	29-07-2011
			EP 2358368 A1	24-08-2011
			JP 2013510072 A	21-03-2013
			KR 20110086700 A	29-07-2011
			MA 32786 B1	01-11-2011
			NZ 592616 A	26-04-2013
			PE 04312011 A1	13-07-2011
			TW 201022237 A	16-06-2010
			US 2010322869 A1	23-12-2010
			US 2011269703 A1	03-11-2011
			US 2012282187 A1	08-11-2012
WO 2010055021 A1	20-05-2010			
-----				
WO 2006103206	A2	05-10-2006	AR 056291 A1	03-10-2007
			AU 2006228600 A1	05-10-2006
			BR PI0608656 A2	19-01-2010
			CA 2602563 A1	05-10-2006
			CN 101151030 A	26-03-2008
			EA 200701841 A1	28-02-2008
			EP 1885354 A2	13-02-2008
			JP 2008534552 A	28-08-2008
			KR 20070116936 A	11-12-2007
			NZ 562775 A	31-03-2011

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2013/071803

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		US 2006222640 A1	05-10-2006	
		US 2010184729 A1	22-07-2010	
		WO 2006103206 A2	05-10-2006	
		ZA 200706698 A	31-12-2008	
-----				
US 6087380	A	11-07-2000	US 6087380 A	11-07-2000
			US 6469039 B1	22-10-2002
			US 2003004181 A1	02-01-2003
-----				